Abstract #0369
1 H MRS detection of glutamate predicts survival in pediatric medulloblastoma
Martin Wilson 1,2 , Simrandip K Gill 1,2 , Lesley MacPherson 2 , Martin English 2 , Theodoros N Arvanitis 2,3 , and Andrew C Peet 1,2
1
School of Cancer Sciences, University of
Birmingham, Birmingham, United Kingdom,
2
Birmingham
Children's Hospital NHS Foundation Trust, Birmingham,
United Kingdom,
3
Institute
of Digital Healthcare, WMG, University of Warwick,
Coventry, United Kingdom
Medulloblastoma is the most common malignant brain
tumour occurring in childhood and the diversity of
outcomes makes this a particularly challenging disease
to treat. In this study,
1
H
MRS was collected from 35 medulloblastoma patients and
metabolite biomarkers were investigated to stratify
high-risk patients. Glutamate was found to predict
survival, and validated prospectively.
1
H
HR-MAS was collected from a sub-set of patients and
agreement between in-vivo and ex-vivo results was found,
adding validation to the assignment of glutamate. The
identification of glutamate as a predictive biomarker of
survival in medulloblastoma provides a clinically viable
measure and multi-center reproduction is warranted.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
